Registry of CytoSorb Therapy in COVID-19 ICU Patients (CTC REGISTRY)
Registry of CytoSorb Therapy in COVID-19 ICU Patients (CTC REGISTRY): Registry of Patient-level Clinical Data on CytoSorb Hemoadsorption Provided Via Integration of the CytoSorb Device Into Extracorporeal Membrane Oxygenation (ECMO), Continuous Renal Replacement Therapy (CRRT), or Hemoperfusion Extracorporeal Circuits in COVID-19 ICU Patients
Sponsor: CytoSorbents Europe GmbH
A observational or N/A phase clinical study on COVID-19, this trial is completed. The trial is conducted by CytoSorbents Europe GmbH and has accumulated 10 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Mar 2024 — Jul 2024 [monthly]
Completed
-
Feb 2022 — Mar 2024 [monthly]
Completed
Status: Recruiting → Completed
-
Jun 2021 — Feb 2022 [monthly]
Recruiting
▶ Show 5 earlier versions
-
Mar 2021 — Jun 2021 [monthly]
Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jun 2020 — Oct 2020 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CytoSorbents Europe GmbH
- CytoSorbents, Inc
For direct contact, visit the study record on ClinicalTrials.gov .